10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds

7. Dyne Therapeutics Inc. (NASDAQ:DYN)

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.

On May 26, Dyne Therapeutics Inc. (NASDAQ:DYN) reached a major regulatory milestone by submitting its official Biologics License Application to the FDA for its new Duchenne muscular dystrophy treatment, z-rostudirsen. The company is seeking a Priority Review designation, which would safely cut down the standard regulatory waiting time from ten months to just six.

On top of that, the management is still planning for a commercial launch in the first quarter of 2027. This rapid progress makes the company a prominent name among growth stocks with upside potential as approvals stay on track.

On May 13, Bernstein increased the firm’s price target on Dyne Therapeutics Inc. (NASDAQ:DYN) from $23 to $24 while retaining a Market Perform rating on the stock. The adjustment leads to a revised upside potential of almost 29%.

With an 11% year-to-date increase, the biotech segment has experienced a solid start to 2026, outpacing both the S&P and the Pharma segment. Smaller names have prospered, with some under the firm’s coverage up 7% YTD on a basic-average measure and down 3% cap adjusted. All in all, Bernstein is optimistic about the industry since it anticipates strong M&A and IPO activity and perceives recent FDA leadership changes as favorable, especially for emerging firms.

Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It uses its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.